Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Blum Capital Cuts Stake in eResearch $ERES $ERT to 9.3%

Richard Blum’s Blum Capital Partners announced on Monday that it sold a large portion of its holding in eResearch Technology, Inc. (ERT, formerly ERES), reducing its sizeable position to a 9.3% stake – almost 20% less than it held at the end of September. Blum Capital Partners had owned 5.54 million shares in the company at the end of the third quarter. According to the 13D filed on January 3, he had cut that percentage to just over 4.60 million shares on December 30, 2011.

On December 30, ERT traded between $4.65-$4.75 a share. It closed January 4 at $4.80 a share. The company has a one-year target estimate of $7.31 ($6.00-$9.00) and carries analyst recommendations of 1.8 on a scale in which 1.0 means “Strong Buy” and 5.0 indicates “Sell.” ERT’s earnings have grown by 3.63% per annum ver the last five years but analysts predict its earnings will grow by 21.50% per annum over the next five years, easily outperforming industry expectations of 14.94% per annum.  ERT’s share price had dipped below $4 around Thanksgiving, but rebounded quickly, hitting a high of $4.70 on December 1.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!